Kura Oncology Inc (NASDAQ:KURA) major shareholder Ecor1 Capital Fund Qualified, bought 119,906 shares of the stock in a transaction dated Thursday, December 6th. The stock was purchased at an average price of $13.50 per share, with a total value of $1,618,731.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of KURA opened at $13.40 on Friday. Kura Oncology Inc has a 1-year low of $10.20 and a 1-year high of $24.02. The stock has a market cap of $497.52 million, a P/E ratio of -8.82 and a beta of 4.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. Research analysts forecast that Kura Oncology Inc will post -1.72 EPS for the current fiscal year.
KURA has been the subject of several analyst reports. BidaskClub lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, September 18th. Zacks Investment Research lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. ValuEngine lowered shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Friday, October 19th. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Kura Oncology in a report on Monday, October 22nd. Finally, Cowen restated a “buy” rating on shares of Kura Oncology in a report on Monday, October 22nd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $26.86.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC purchased a new position in Kura Oncology during the 2nd quarter valued at about $187,000. BlueMountain Capital Management LLC increased its position in Kura Oncology by 2,315.9% during the 3rd quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock valued at $189,000 after purchasing an additional 10,329 shares during the period. Trexquant Investment LP purchased a new position in Kura Oncology during the 3rd quarter valued at about $217,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Kura Oncology during the 2nd quarter valued at about $218,000. Finally, BB&T Securities LLC purchased a new position in Kura Oncology during the 2nd quarter valued at about $291,000. 79.28% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Ecor1 Capital Fund Qualified, Buys 119,906 Shares of Kura Oncology Inc (KURA) Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/08/ecor1-capital-fund-qualified-buys-119906-shares-of-kura-oncology-inc-kura-stock.html.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Treasury Bonds
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.